Dr. Jibing Liu 刘吉兵
Chief Physician
Department of Interventional Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional treatment for liver, biliary, colorectal, pancreatic, lung, and esophageal cancers. Procedures include stent placement, biliary drainage, portal vein stenting, ultrasound/CT/DSA-guided microwave and radiofrequency ablation, and 3D-printed template-assisted particle implantation.
Dr. Liu is Director of the First Interventional Ward, Chief Physician, Professor, and Master’s Supervisor at Shandong Cancer Hospital. Dr. Liu graduated from Qingdao University Medical College in 1999 and has worked in the Interventional Department since 2006.
Professional roles
- Vice Chair, Interventional Oncology Branch, Shandong Anti-Cancer Association
- Vice Chair, Tumor Minimally Invasive Branch, Shandong Medical Association
- Chair, Tumor Minimally Invasive Physicians Branch, Shandong Medical Doctor Association
- Standing Committee Member, Interventional Committee, Bethune Spirit Research Association
Name order: in Chinese the family name comes first (Liu Jibing). Papers usually list the name as Jibing Liu or Liu J.
Selected publications
24 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Lett, 2026 (senior author): Brain-derived neurotrophic factor in solid tumor angiogenesis and neurovascular-immune interactions (Review). PubMed 42889736
- Chin Med J (Engl), 2026 (senior author): Double spring coil transarterial chemoembolization approach integrating with sorafenib for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective cohort study. PubMed 42087297
- Cancer Biol Ther, 2024 (senior author): Expression and clinical significance of NLRC5 in hepatocellular carcinoma. PubMed 39132868
- Medicine (Baltimore), 2021 (senior author): CalliSpheres drug-eluting beads transarterial-chemoembolization in the treatment of liver metastases from breast cancer: Initial experience in 14 patients. PubMed 34967376
- Medicine (Baltimore), 2021 (first author): Effect of partial splenic embolization on transarterial chemoembolization for hepatocellular carcinoma with hypersplenism. PubMed 34190168
- Arch Toxicol, 2021 (first author): N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization. PubMed 33713148
- Tumour Biol, 2015 (first author): miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma. PubMed 25230788
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion